Understanding how malaria parasites in Africa respond to new antimalarial drugs
Mechanisms of varied sensitivity of P. falciparum field isolates to the antimalarial drug pipeline
This study is looking at how malaria parasites from Uganda and Burkina Faso respond to new medicines, hoping to find out why some are harder to treat than others, so that we can create better treatments for patients like you.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, San Francisco NIH-funded |
| Lab location | 1 site (San Francisco, United States) |
| Project ID | NIH-10884299 on NIH RePORTER |
What this research studies
This research investigates the sensitivity of malaria parasites, specifically P. falciparum, to new antimalarial drugs being developed. By analyzing fresh field isolates from Uganda and Burkina Faso, the study aims to identify the mechanisms that contribute to varying levels of drug resistance. The approach combines high-throughput genotypic characterization with assessments of drug susceptibility, providing insights that could inform the development of more effective combination therapies. Patients may benefit from improved treatment options as a result of this research.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals in Africa who are infected with P. falciparum malaria.
Not a fit: Patients who are not infected with malaria or those living outside the regions of Uganda and Burkina Faso may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to the development of more effective antimalarial treatments that overcome drug resistance.
How similar studies have performed: Previous research has shown success in understanding drug resistance mechanisms in malaria, indicating that this approach has potential for impactful findings.
Where this research is happening
San Francisco, United States
- University of California, San Francisco — San Francisco, United States (Active)
Researchers
- Principal investigator: Rosenthal, Philip Jon — University of California, San Francisco
- Study coordinator: Rosenthal, Philip Jon
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.